Alnylam is the industry leader in the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to address the unmet needs of patients with debilitating diseases. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality and is now advancing a robust pipeline of investigational RNAi therapeutic medicines. Please visit www.alnylam.com for more information. […]
The Director of Global Patient Safety and Risk Management role is to provide guidance and expertise on all aspects of clinical safety throughout the entire...